Trial Update November 12, 2026

Survodutide Phase 1 Trial Status Updated to Active, Not Recruiting

On November 12, 2026, the clinical trial registry listed an update for a study of survodutide, an unapproved compound still in research. The trial, titled "A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity," is registered under identifier NCT06745284.

The study is a Phase 1 trial. Its current status is listed as active, not recruiting, meaning the trial is ongoing but no longer enrolling new participants. No results have been reported as part of this status update.

This record reflects only administrative trial information available through the public registry. The trial's title indicates it is designed to examine aspects of energy utilization and fat metabolism in people with obesity, but no outcome data, findings, or conclusions are included in this update. Survodutide remains classified as an unapproved compound under research and has not received regulatory approval for any indication.

Readers interested in the broader research context, including the compound's current development stage and regulatory status, can consult the survodutide overview page for additional background.

See the full survodutide overview

Source: https://clinicaltrials.gov/study/NCT06745284